Table 2 The main pharmacokinetic parameters after oral administration of 25, 50, and 100 mg/kg for MOIG, and 1650 mg/kg for MO or intravenous administration of 25 mg/kg MOIG in female rats (n = 3, mean ± SD)
Parameters | Component | po-MOIG-25 | po-MOIG-50 | po-MOIG-100 | po-MO-1650 | iv-MOIG-25 |
|---|---|---|---|---|---|---|
AUC0-t (μg·h/L) | MON | 1988 ± 870 | 3083 ± 1184 | 2963 ± 397 | 1504 ± 244 | 19,098 ± 4740 |
DA | 3133 ± 1580 | 6572 ± 884 | 5727 ± 992 | 4254 ± 3301 | 8910 ± 2343 | |
AUC0-∞ (μg·h/L) | MON | 2040 ± 815 | 3178 ± 1290 | 2981 ± 400 | 1507 ± 243 | 19,129 ± 4743 |
DA | 3221 ± 1536 | 6661 ± 935 | 5785 ± 1024 | 4308 ± 3367 | 8945 ± 2349 | |
AUMC0-∞ (μg·h/L) | MON | 10,005 ± 3510 | 16,892 ± 14,358 | 8895 ± 1596 | 5589 ± 407 | 17,847 ± 2842 |
DA | 20,444 ± 6912 | 41,101 ± 9585 | 29,163 ± 7495 | 25,789 ± 23,049 | 9214 ± 715 | |
MRT (h) | MON | 5.28 ± 2.38 | 4.78 ± 2.64 | 2.99 ± 0.43 | 3.75 ± 0.34 | 0.98 ± 0.31 |
DA | 6.77 ± 1.35 | 6.12 ± 0.60 | 4.99 ± 0.44 | 5.66 ± 0.71 | 1.08 ± 0.31 | |
t1/2 (h) | MON | 3.61 ± 1.03 | 4.01 ± 2.35 | 2.08 ± 0.50 | 2.51 ± 0.34 | 1.76 ± 1.32 |
DA | 4.43 ± 1.12 | 3.66 ± 0.35 | 3.64 ± 0.43 | 3.38 ± 0.44 | 2.20 ± 1.86 | |
Tmax (h) | MON | 0.94 ± 0.00 | 1.33 ± 0.29 | 0.92 ± 0.14 | 0.92 ± 0.14 | 0.03 ± 0.00 |
DA | 2.17 ± 0.76 | 1.83 ± 0.58 | 2.33 ± 0.58 | 2.08 ± 1.18 | 0.03 ± 0.00 | |
Vd (L/g) | MON | 0.08 ± 0.05 | 0.09 ± 0.04 | 0.10 ± 0.04 | 4.07 ± 1.16 | 0.003 ± 0.002 |
DA | 0.07 ± 0.06 | 0.04 ± 0.01 | 0.09 ± 0.01 | 2.50 ± 1.25 | 0.009 ± 0.006 | |
CL (L/g·h) | MON | 0.014 ± 0.005 | 0.018 ± 0.009 | 0.034 ± 0.05 | 1.114 ± 0.183 | 0.001 ± 0.000 |
DA | 0.010 ± 0.006 | 0.008 ± 0.001 | 0.018 ± 0.003 | 0.532 ± 0.287 | 0.003 ± 0.001 | |
Cmax (μg/L) | MON | 475 ± 160 | 761 ± 184 | 899 ± 197 | 405 ± 102 | 25,719 ± 12,174 |
DA | 445 ± 218 | 863 ± 112 | 966 ± 171 | 584 ± 419 | 12,340 ± 5992 | |
F (%) | MON | 10.66 ± 4.26 | 8.31 ± 3.37 | 3.90 ± 0.52 | 3.94 ± 0.64 | – |
DA | 36.01 ± 17.17 | 37.23 ± 5.23 | 16.17 ± 2.86 | 24.08 ± 18.82 | – |